What's The Scoop On Häagen-Dazs’ Evolving Media Mix?
Häagen-Dazs launched its new “Slow” campaign earlier this year, hoping to strike a chord with a diverse array of consumers across platforms.
Häagen-Dazs launched its new “Slow” campaign earlier this year, hoping to strike a chord with a diverse array of consumers across platforms.
In the next two years, linear TV will be deprioritized so much that holding companies will begin outsourcing their linear buying.
The alternative currency bucket could use a rebrand. That referential and somewhat deferential phraseology – a reference to Nielsen – drives Peter Liguori, VideoAmp’s executive chairman, a little nuts. It stems, he argues, from the “absurd notion” that the TV industry “has almost 100% of its eggs in one basket.”
Even with the amazing storylines, this NBA season brought a steep decline in local TV viewership. While it’s tempting to frame this as waning fan interest, these drops are symptoms of a media ecosystem in transition.
Emarketer is predicting tariffs could lead to a $2.78 billion to $4 billion decline in linear TV upfront spending, but CTV spending will be flat to up. Emarketer analyst Ross Benes unpacks these findings. Plus: At the Possible conference, optimism reins.
Agentic AI aims to take the work out of campaign targeting; marketers are increasingly using retail media data in non-retail channels; and Puma drives sales by re-embracing its branding.
Agencies around the globe weigh in on principal-based buying; live sports are king, but new sports like F1 are having trouble gaining traction; and Adobe gets roasted by Bluesky’s artist community.
NBC, Fubo, Disney-owned ESPN and ad agency Mindshare weigh in on the creative flexibility offered on CTV and whether sports streamers really reach incremental audiences.
What happens if the TikTok ban comes to pass; Netflix’s live sports Hail Mary play; and Channel Factory surfs for buyers.
The odds of RFK Jr. implementing a ban on TV drug ads are slim, says our guest this week, BranchLab’s Josh Walsh. Still, pharma advertisers could face other regulatory changes over the next four years. Plus: We break down Forrester’s picks for the top 10 SSPs.